The Center for testing and clinical investigations of new medicines of Uzhhorod National University was established by the order of rector of Uzhgorod National University 10 / 01-03 dated on October 24^th 2005 "About Creation of Scientific Research Center" for the purpose of develop new treatments, the introduction into clinical practice the effective medicines for realization the order of the Ministry of Defence.

In November 7^th 2003 according to the order №5.12-6716 / A the Ministry of Health of Ukraine the State Pharmacological Centre the Sector of Coordination and Monitoring Clinical medicines, the Center for testing and clinical investigations of new medicines of Uzhhorod National University are included to " The List of Health Care Institutions eligible to conduct Clinical Testing Medicines"(the Order №396 of the Ministry of the Health of Ukraine of 26.08.2003).

The Center for testing and clinical investigations of new medicines of Uzhhorod National University is engaged in scientific practical and research work at the Department of Oncology and Radiology Institute of Continuing Education and the university training of Uzhgorod National University at the Urban Cancer Center of the Central Urban Hospital according to the agreement "About Scientific Practical Cooperation "of April 15^th 2009. In the center works collective of the Department at the head of the Department E. Hotko.

The Center cooperates with the leading pharmaceutical companies and companies engaged in organization of conducting clinical research (Quintiles, Pharmanet, Icon, PPD, GlaxoSmitcline, PSI, Parexel, etc.).

The clinical research conducted on nosologies: head and neck cancer, lung cancer, prostate cancer, breast cancer, cancer of the thick and thin intestine, stomach cancer, melanoma, endometrial cancer, kidney cancer, pancreatic cancer, neuroendocrine tumor.

For the period of 2006, the Center for testing and clinical investigations of new medicines was done 112 clinical research. Within the clinical research work was carried out to assess the efficiency and toxicity of new medicines compared with a standard scheme of chemotherapy, targeted therapy, immunotherapy, as well as assess the quality of life and time to progression of the underlying disease and survival of patients. The positive results was obtained  in improving the quality and increasing time to progression of the underlying disease, the extension of timelife of the patients.